Marumoto Hirokazu, Tsuboi Nobuo, Kawamura Tetsuya, Yokoo Takashi
Kidney Med. 2020 Aug 10;2(5):620-628. doi: 10.1016/j.xkme.2020.07.002. eCollection 2020 Sep-Oct.
RATIONALE & OBJECTIVE: Studies of immunoglobulin A nephropathy (IgAN) have suggested the therapeutic benefit of simultaneously adding tonsillectomy to corticosteroid therapy. However, the efficacy of tonsillectomy monotherapy in the absence of simultaneous use of corticosteroids is unclear.
Patients with IgAN treated with tonsillectomy monotherapy were analyzed retrospectively. Clinical parameters, including kidney function slope, were compared before and after tonsillectomy.
SETTING & PARTICIPANTS: Patients with biopsy-proven IgAN who received tonsillectomy monotherapy at our hospital between 2007 and 2018.
20 Japanese patients with IgAN were included in this study (mean follow-up period, 135 months from initial biopsy diagnosis to tonsillectomy). All patients had been treated with renin-angiotensin-aldosterone system inhibitors. 17 patients had a history of induction therapy with corticosteroids. Mean time to tonsillectomy from termination of corticosteroid therapy was 84 months. Hematuria, proteinuria, and clinical remission were achieved in 13 of 17 (76%), 10 of 17 (59%), and 8 of 20 (40%) patients at medians of 3.0, 6.0, and 13.5 months, respectively, after tonsillectomy. The slope of the estimated glomerular filtration rate (eGFR) increased significantly during the 81-month observation period, including the periods before and after tonsillectomy (-2.59 vs 1.05 mL/min/1.73 m per year; < 0.001). The effect on eGFR slope was consistent in 11 patients with reduced GFR (eGFR < 60 mL/min/1.73 m) at the time of tonsillectomy (-3.07 vs -0.39 mL/min/1.73 m per year; < 0.001).
Small sample size. Lack of a control (no-tonsillectomy) group due to the difficulty of setting the baseline time point (which corresponded to tonsillectomy in our sample). Potential exclusion of patients with the most severe disease who are likely to receive corticosteroids. Lack of generalizability to patients in other countries.
Tonsillectomy monotherapy may prevent kidney function decline in some patients with IgAN with kidney disease that has been progressive despite long-term application of conventional therapies.
免疫球蛋白A肾病(IgAN)的研究表明,在糖皮质激素治疗的同时加做扁桃体切除术具有治疗益处。然而,在不同时使用糖皮质激素的情况下,扁桃体切除术单一疗法的疗效尚不清楚。
对接受扁桃体切除术单一疗法的IgAN患者进行回顾性分析。比较扁桃体切除术前和术后的临床参数,包括肾功能斜率。
2007年至2018年期间在我院接受扁桃体切除术单一疗法且经活检证实为IgAN的患者。
本研究纳入了20例日本IgAN患者(从初始活检诊断到扁桃体切除术的平均随访期为135个月)。所有患者均接受了肾素-血管紧张素-醛固酮系统抑制剂治疗。17例患者有糖皮质激素诱导治疗史。从糖皮质激素治疗结束到扁桃体切除术的平均时间为84个月。扁桃体切除术后,17例患者中的13例(76%)、17例患者中的10例(59%)和20例患者中的8例(40%)分别在3.0、6.0和13.5个月的中位时间实现了血尿、蛋白尿缓解及临床缓解。在包括扁桃体切除术前和术后的81个月观察期内,估计肾小球滤过率(eGFR)斜率显著增加(-2.59 vs 1.05 mL/min/1.73m²每年;P<0.001)。扁桃体切除术时GFR降低(eGFR<60 mL/min/1.73m²)的11例患者中,对eGFR斜率的影响是一致的(-3.07 vs -0.39 mL/min/1.73m²每年;P<0.001)。
样本量小。由于难以设定基线时间点(在我们的样本中对应于扁桃体切除术),缺乏对照组(未行扁桃体切除术组)。可能排除了可能接受糖皮质激素治疗的最严重疾病患者。对其他国家的患者缺乏普遍性。
对于一些尽管长期应用传统疗法但肾病仍呈进行性发展的IgAN患者,扁桃体切除术单一疗法可能预防肾功能下降。